Oligopeptides for Cancer Immunotherapy
Cytotoxic T lymphocytes (CTL) kill tumour cells upon recognition of oligopeptides derived from tumour-associated antigens (TAA). These are presented by major histocompatibility complex (MHC) class I molecules on the surface of the tumour cells. TAA of certain categories differ with respect to their tumour specificity: mutated antigens and so-called “cancer/germ line” (C/G) antigens are considered strictly or highly tumour specific whereas differentiation antigens are expressed in tumours and the tissues the tumours originate from. The expression of C/G antigens was demonstrated in a variety of cancer types.
Further Information: PDF
IMG Innovations-Management GmbH
Phone: +49 (0)631/31668-50
Contact
Dr. Klaus Kobek
Media Contact
All latest news from the category: Technology Offerings
Newest articles
A universal framework for spatial biology
SpatialData is a freely accessible tool to unify and integrate data from different omics technologies accounting for spatial information, which can provide holistic insights into health and disease. Biological processes…
How complex biological processes arise
A $20 million grant from the U.S. National Science Foundation (NSF) will support the establishment and operation of the National Synthesis Center for Emergence in the Molecular and Cellular Sciences (NCEMS) at…
Airborne single-photon lidar system achieves high-resolution 3D imaging
Compact, low-power system opens doors for photon-efficient drone and satellite-based environmental monitoring and mapping. Researchers have developed a compact and lightweight single-photon airborne lidar system that can acquire high-resolution 3D…